| Autor: |
Vermeij, Renee, Daemen, Toos, Bock, Geertruida H. de, Graeff, Pauline de, Leffers, Ninke, Lambeck, Annechien, Hoor, Klaske A. ten, Hollema, Harry, Zee, Ate G. J. van der, Nijman, Hans W. |
| Předmět: |
|
| Zdroj: |
Clinical & Developmental Immunology; 2010, p1-8, 8p, 6 Charts |
| Abstrakt: |
The prognosis of epithelial ovarian cancer (EOC), the primary cause of death fromgynaecologicalmalignancies, has onlymodestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a "universal" vaccine strategy.We determined the expression of tumor antigens in the context of MHC class I expression in 270 primary tumor samples using tissue microarray. Expression of tumor antigens p53, SP17, survivin, WT1, and NY-ESO-1 was observed in 120 (48.0%), 173 (68.9%), 208 (90.0%), 129 (56.3%), and 27 (11.0%) of 270 tumor specimens, respectively. In 93.2% of EOC, at least one of the investigated tumor antigens was (over)expressed. Expression of MHC class I was observed in 78.1% of EOC. In 3 out 4 primary tumors, (over)expression of a tumor antigen combined with MHC class I was observed. These results indicate that a multiepitope vaccine, comprising these antigens, could serve as a universal therapeutic vaccine for the vast majority of ovarian cancer patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
